A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (mRNA-4157-P201)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Melanoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Has a diagnosis of resectable cutaneous melanoma (per American Joint Committee on Cancer [AJCC], 8th edition) with histologically confirmed cutaneous melanoma that was metastatic to a lymph node at one of the following stages: a)Stage IIIB, only if

You may not be eligible for this study if the following are true:

  • 1) Has a history of a hematologic or primary solid tumor malignancy (other than cutaneous melanoma under study), unless there has been no evidence of that disease for at least 5 years prior to study entry. 2) Has an active autoimmune disease (excludin


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.